Back at the beginning of the year I surveyed you readers here on The Niche about the future of CIRM and whether California voters would approve more funding for it in November. That funding effort is now on the ballot as Proposition 14. A month earlier late in 2019 in my yearly 20 predictions for […]
Polls: will California approve Prop 14 to fund CIRM again? Should it? Read More »
Introduction to CAR-T cells CAR-T cells are an exciting cutting-edge technology that has been garnering great interest including in the stem cell field. Potential therapeutic uses of CAR-T, which stands for Chimeric Antigen Receptor T-Cells (CAR-T), are being studied in clinical trials as immunotherapies to potentially fight cancer as well as many other diseases by
CAR-T cells review: cancer & a critical look at possible uses in aging & COVID-19 Read More »
There is always plenty of complicated, mixed-bag news on the stem cell and regenerative medicine front so it’s great to highlight when there’s some good news out there. Today’s post includes several such upbeat items. At the bottom I’ve included a list of some recent interesting publications as well. Good news on vision front: jCyte
Stem cell & regenerative medicine good news & pubs Read More »
I recently started 2 polls on the future of CIRM. The polls are focused on the effort led by Robert Klein to get more funding from the State of California for the stem cell agency. They asked readers about whether Californians will refund CIRM and whether Californians should refund CIRM. Basically, the polls are asking
Upbeat poll results on the future of CIRM funding Read More »
Scientist He Jiankui(贺建奎) has been sentenced to 3 years in prison by Chinese authorities. Two collaborators also will go to jail. A piece in Science by Dennis Normile on the sentencing of He Jiankui ID’d the other two: “His collaborators were identified as Zhang Renli, of a medical institution in Guangdong province, and Qin Jinzhou, from a Shenzhen
Perspectives on CRISPR baby guy He Jiankui (贺建奎) going to jail Read More »
Take our poll: what will be the fates of the stem cell clinic firms sued by the FDA one year from now in October 2019? To be clear, I am asking for your predictions, not what you hope will be the situation a year from now. U.S. Stem Cell, Inc. (USRM) and California Stem Cell
Polls on futures of stem cell clinics sued by FDA Read More »
What happens when one of the most exciting stem cell biotechs ViaCyte teams up with a firm like CRISPR Therapeutics to use a combination of gene editing and cell therapy? Hopefully a synergistic partnership emerges that in this case can develop an effective stem cell-based therapy for diabetes. You can see a press release on
ViaCyte & CRISPR Therapeutics team up to battle diabetes Read More »
I’m doing a Facebook Live question and answer on stem cells today, Monday, July 23 at Noon USA Pacific Time. Hopefully we’ll cover the exciting, legit research as well as the challenges in the field these days such as for-profit, unproven stem cell clinics out there, as well as everything in between. One possible good
Ask Your Questions on Knoepfler Facebook Live on Stem Cells Today at Noon Read More »
Periodically I also try to post (as I am today) specifically about stem cell good news amongst all the swirling developments out there. You can see the most recent past installment focused on good news here that include vascularized organoids. I recently stumbled on this quote that for me linked up the potential of stem cells
3 bits of stem cell good news Read More »
At the request of the FDA, the DOJ is suing for permanent injunctions against two stem cell clinic firms, U.S. Stem Cell, Inc. and California Stem Cell Treatment Center (and for the latter, its parent chain of around 100 clinics, Cell Surgical Network). What does this big development mean in practical terms and how might it
Helpful Zettler insights from Q&A on FDA suits against stem cell clinics Read More »